APLT250117P15000
- 0.00
- 0.000.00%
Applied Therapeutics Newsroom
This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
Top Premarket Decliners
William Blair Downgrades Applied Therapeutics to Market Perform
William Blair Downgrades Applied Therapeutics(APLT.US) to Hold Rating
William Blair Downgrades Applied Therapeutics (APLT) to a Hold
RBC Capital Maintains Applied Therapeutics(APLT.US) With Hold Rating, Cuts Target Price to $1.5
Applied Therapeutics Is Maintained at Sector Perform by RBC Capital
Applied Therapeutics Price Target Cut to $1.50/Share From $4.00 by RBC Capital
Applied Therapeutics Analyst Ratings
Applied Therapeutics CEO Shendelman Steps Down
Applied Therapeutics Faces Leadership Changes and Regulatory Hurdles
Express News | Applied Therapeutics Inc - Funtleyder to Continue as CFO While Serving as Interim CEO
Express News | Applied Therapeutics Inc - Shoshana Shendelman Steps Down as CEO
Press Release: Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Express News | Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Express News | Applied Therapeutics Inc : RBC Cuts Target Price to $1.5 From $4
Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx
Express News | Applied Therapeutics Inc - Joel Marcus Resigns From Applied Therapeutics Board
Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors
(APLT) - Analyzing Applied Therapeutics's Short Interest